Carl Zeiss Meditec AG
AFX
주식 순위
#4521
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest... Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
주가
$38.61
시가총액
$3.38B
변동 (1일)
-3.58%
변동 (1년)
-30.25%
국가
DE
거래 Carl Zeiss Meditec AG (AFX)
카테고리
Healthcare
Carl Zeiss Meditec AG (AFX)의 매출
Oct 2026 기준 매출 TTM: 0
Carl Zeiss Meditec AG의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Carl Zeiss Meditec AG의 수익 기록 (2026 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 제공된 날짜에 대한 데이터가 충분하지 않습니다. | ||
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $11.03B | - |
US
|
|
| $34.74B | - |
FR
|
|
| - | - |
JP
|
|
| $20.84B | - |
US
|
|
| - | - |
CH
|
